Preliminary results are expected in September.
Predix Pharmaceuticals Holdings Inc. today announced that it has completed enrollment for its first Phase III trial of PRX-00023, the company's treatment for patients with generalized anxiety disorder (GAD). The results of the trial will arrive in two stages; the preliminary results are due in the second half of 2006.
At a press conference to announce Predix’s merger with Epix Pharmaceuticals, Inc. (Nasdaq: EPIX), the company said results from the trial could be expected in September.
Predix discovers and develops novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. Predix recently merged with Epix at a company value of $90 million for Predix. The market cap of the merged company is currently $67.2 million.
Published by Globes [online], Israel business news - www.globes.co.il - on May 25, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006